Jagsonpal Pharmaceuticals Submits Q4FY26 SEBI Compliance Certificate for Dematerialization Process

1 min read     Updated on 11 Apr 2026, 09:20 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Jagsonpal Pharmaceuticals Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate, issued by registrar MCS Share Transfer Agent Limited, confirms proper handling of securities dematerialization process and compliance with regulatory requirements. The company communicated this filing to BSE and NSE, demonstrating its commitment to regulatory adherence.

powered bylight_fuzz_icon
37425010

*this image is generated using AI for illustrative purposes only.

Jagsonpal Pharmaceuticals Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company filed the certificate for the quarter ended March 31, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Compliance Details

The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which governs the dematerialization process of securities. MCS Share Transfer Agent Limited, serving as the company's registrar and share transfer agent, provided the certification dated April 6, 2026.

Parameter: Details
Quarter Ended: March 31, 2026
Certificate Date: April 6, 2026
Filing Date: April 10, 2026
Registrar: MCS Share Transfer Agent Limited
Regulation: SEBI Regulation 74(5)

Certification Confirmations

The registrar certified compliance with key dematerialization requirements for the quarter. The certificate confirms that within 15 days of receipt of securities for dematerialization:

  • Securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed
  • Certificates have been duly verified, mutilated, and cancelled after proper verification
  • The depository name has been substituted in records as the registered owner

Stock Exchange Communication

Jagsonpal Pharmaceuticals communicated the compliance filing to both major Indian stock exchanges. The company is listed on BSE Limited with scrip code 507789 and on National Stock Exchange of India Limited with the symbol JAGSNPHARM.

Exchange: Details
BSE Scrip Code: 507789
NSE Symbol: JAGSNPHARM
Company Secretary: Pratham Rawal
CIN: L74899DL1978PLC009181

Corporate Information

The pharmaceutical company operates from its corporate office located at Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram, Haryana. Pratham Rawal, serving as Company Secretary and Compliance Officer, signed the regulatory filing on behalf of the company. This quarterly certification represents part of the company's ongoing regulatory compliance framework, ensuring adherence to SEBI guidelines for depositories and participants in the securities market.

Historical Stock Returns for Jagsonpal Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+0.88%+4.51%+10.14%-11.85%-7.64%+526.19%

What strategic initiatives might Jagsonpal Pharmaceuticals announce in their upcoming annual results for FY2026?

How could potential changes to SEBI's dematerialization regulations impact pharmaceutical companies' compliance costs?

Will Jagsonpal Pharmaceuticals consider expanding its stock exchange listings to international markets given its strong compliance track record?

Jagsonpal Pharmaceuticals
View Company Insights
View All News
like15
dislike

Jagsonpal Pharmaceuticals Publishes Postal Ballot Notice for ₹40 Crore Buyback

2 min read     Updated on 27 Mar 2026, 09:34 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Jagsonpal Pharmaceuticals has published newspaper advertisements confirming the dispatch of its postal ballot notice for a ₹40 crore share buyback proposal. The company seeks approval to buy back 16 lakh equity shares at ₹250 per share through e-voting from March 26 to April 24, 2026, with the buyback price offering a significant premium over current market rates.

powered bylight_fuzz_icon
36005471

*this image is generated using AI for illustrative purposes only.

Jagsonpal Pharmaceuticals Limited has published newspaper advertisements confirming the dispatch of its postal ballot notice for a ₹40 crore share buyback proposal. The company sent the notice to stock exchanges on March 26, 2026, in compliance with SEBI regulations, following the earlier announcement of the buyback proposal.

Buyback Proposal Details

The company proposes to buy back up to 16,00,000 fully paid-up equity shares of face value ₹2 each at a price of ₹250 per share. This buyback represents 2.39% of the total number of equity shares in the company's paid-up equity share capital.

Parameter: Details
Number of Shares: 16,00,000 (Sixteen lakhs)
Face Value: ₹2 per share
Buyback Price: ₹250 per share
Maximum Buyback Size: ₹40,00,00,000 (₹40 crore)
Percentage of Capital: 2.39% of paid-up equity
Percentage of Reserves: 18.35% of paid-up capital and free reserves

Newspaper Publication and Compliance

In a letter dated March 26, 2026, to BSE Limited and National Stock Exchange of India Limited, the company submitted copies of newspaper advertisements published in Business Standard (English and Hindi editions). The publication was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The postal ballot notice was electronically dispatched to shareholders on March 25, 2026, whose email addresses are registered with the company, depositories, or registrar and transfer agent.

E-Voting Schedule and Process

The company has engaged National Securities Depository Limited (NSDL) to provide e-voting facilities to all shareholders. The voting process will be conducted entirely through electronic means.

Voting Timeline: Details
Start Date: Thursday, March 26, 2026 at 9:00 AM (IST)
End Date: Friday, April 24, 2026 at 5:00 PM (IST)
Cut-off Date: Friday, March 20, 2026
Result Declaration: Within two working days of voting conclusion

Shareholders whose names appear in the Register of Members or List of Beneficial Owners as on March 20, 2026, will be eligible to participate in the e-voting process.

Premium Over Market Price

The proposed buyback price of ₹250 per share represents a substantial premium over the prevailing market prices. The buyback price offers a premium of 43.55% and 44.23% over the closing prices on BSE and NSE respectively on March 6, 2026, being the day preceding the intimation date. The closing market prices on March 6, 2026, were ₹174.15 on BSE and ₹173.34 on NSE.

Financial Framework and Compliance

The maximum buyback offer size of ₹40 crore represents 18.35% of the aggregate paid-up equity share capital and free reserves as of March 31, 2025, which is within the prescribed limit of 25% under applicable regulations. The company has appointed Centrum Capital Limited as the SEBI registered Merchant Banker to manage the buyback process.

Mr. Ayush Khandelwal (ACS A41316, COP 19171), Proprietor of Ayush Khandelwal & Associates, Practicing Company Secretaries, has been appointed as the scrutinizer to ensure fair and transparent voting.

Shareholder Participation

All equity shareholders and beneficial owners as on the record date, excluding promoters and members of the promoter group, will be eligible to participate in the buyback. A minimum of 15% of the total number of shares proposed for buyback will be reserved for small shareholders.

The postal ballot notice and results will be made available on the company's website at www.jagsonpal.com and NSDL's e-voting portal at www.evoting.nsdl.com . If passed by the requisite majority, the resolution will be deemed to have been passed on Friday, April 24, 2026.

Historical Stock Returns for Jagsonpal Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+0.88%+4.51%+10.14%-11.85%-7.64%+526.19%

What strategic initiatives or growth investments might Jagsonpal Pharmaceuticals pursue with the improved financial metrics following this buyback?

How could the 43% premium buyback price impact investor expectations for future share price performance in the pharmaceutical sector?

Will this buyback signal trigger similar capital return strategies among other mid-cap pharmaceutical companies in the current market environment?

Jagsonpal Pharmaceuticals
View Company Insights
View All News
like18
dislike

More News on Jagsonpal Pharmaceuticals

1 Year Returns:-7.64%